GXH swings to net debt as PBT falls 17% and final dividend cut 43%

What changed

Revenue rose 2.1% to $503.9m, but earnings deteriorated at every line. Operating profit (EBIT) fell 7.3% to $31.8m and PBT fell 17.3% to $22.4m. Reported NPAT attributable to shareholders dropped 74% to $11.8m, but the cleaner read is continuing-operations profit, which fell from $20.3m to $15.8m; the headline gap is explained by FY23 including a $30.3m gain on a discontinued operation versus a $0.3m loss in FY24.

Operating cash flow was essentially flat at $46.0m, yet cash fell $34.8m to $23.4m while gross borrowings rose 48.5% to $34.9m, moving the group from a ~$34.7m net cash position to ~$11.5m net debt. Equity fell $35.4m to $166.6m. The final dividend was cut from 3.5cps to 2.0cps. Pharmacy Services (72% of revenue) saw segment profit fall to $19.3m (~5.3% margin vs 5.9%); Medical Services profit fell to $15.0m (~10.7% margin vs 12.2%).

What matters

• Balance-sheet direction has reversed. A ~$46m swing in net cash/debt alongside unchanged operating cash flow implies capital was deployed below the OCF line — capex ticked up to $7.4m, but the gap is larger than reinvestment and dividends alone explain, so the cash release is the single most material signal for the forward read on leverage.
• Earnings quality softened before tax. PBT down 17.3% on revenue up 2.1% signals margin compression across both segments, explicitly attributed to inflation, weaker retail spend and lower COVID-related higher-margin activity. ROE almost a third of last year's (7.1% vs 22.4%) amplifies the operating deterioration.
• Dividend signal. The 43% cut in the final dividend is directionally consistent with management preserving cash given the balance-sheet shift, notwithstanding that pre-lease FCF of $38.6m still covered the distribution comfortably on the face of it.

Expectations

No quantified guidance or forward-work balance was provided, so run-rate versus target cannot be assessed. HY24 delivered 49.6% of FY24 revenue and 47.7% of NPAT, so the shape was only modestly second-half weighted — there is no evidence of a sharp second-half rebound that would reframe the full-year read. The release itself frames the margin pressures (inflation, retail softness, lower COVID activity) as ongoing rather than one-off, which the numbers support.

Quality of result

Operating cash flow of $46.0m was actually assisted by a $4.2m release from operating working capital (receivables and inventory both lower; receivable days improved from ~10 to ~8). Stripping that, underlying cash conversion would have been below the flat headline, which matters given EBIT fell 7.3%. Pre-lease FCF of $38.6m (vs $40.2m) is credible but also reflects an almost three-fold FCF/NPAT ratio largely because NPAT is depressed by the absence of the prior-year discontinued-operation gain — not because underlying cash generation stepped up.

Segment margin compression in both Pharmacy Services and Medical Services, with no offsetting mix or pricing lever disclosed, suggests the EBIT decline is operating in nature rather than timing-driven.

Unresolved

• What drove the $34.8m cash decline and $11.4m increase in borrowings when OCF less capex less dividends does not fully explain the drawdown — acquisitions, lease repayments, or distributions to non-controlling interests are candidates but are not reconciled in the supplied excerpts.
• Whether the 2.0cps final dividend reflects a reset payout policy or a one-year adjustment, and how it sits against a full-period dividend total that is not specified here.
• Whether inflation and retail-spend pressure in Pharmacy Services are stabilising into FY25, given no forward work or guidance was supplied.
• Why the effective tax rate rose to 29.4% from 25.1%, and whether that is structural.

This briefing cannot assess valuation, management commentary beyond the quoted release excerpts, or any segment-level forward outlook, as none of those were supplied.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.